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A commentary on TREAT: The trial of early




Polyarticular juvenile idiopathic arthritis (JIA) is a category of JIA where multiple joints are affected by chronic
inflammation, and where serious and lasting damage to joints is the expected natural history in untreated disease.
There is evidence of response to disease-modifying antirheumatic and biologic drugs, but little evidence of
permanent remission from any of the existing therapeutic trials. The TREAT trial by Wallace et al., recently published
in Arthritis and Rheumatism, used a collaborative multicenter approach to studying early aggressive treatment of
polyarticular JIA in an attempt to achieve full clinical inactive disease after 6 months of treatment. The study’s main
finding that the earlier in the disease course that treatment is started, the better the chance of disease control, has
provided evidence that there is a ‘window of opportunity’ for treating JIA as there is in adult rheumatoid arthritis
(RA). The study provides both a platform and an impetus for concentrating future treatment trials on early rather
than established disease and investigating a standard of starting treatment within 10 to 12 weeks.
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Background
The term juvenile idiopathic arthritis (JIA) is used to
cover a group of conditions in childhood from infancy
to the age of 17 where arthritis is the main feature and
is truly idiopathic (that is, where no definite infective,
malignant, hematological or other autoimmune cause is
found for the arthritis). There are various subtypes
defined in the JIA spectrum, agreed by expert consensus
(International League of Associations for Rheumatology
(ILAR) criteria) [1,2] to be as near to individual disease
entities as possible, especially for the purpose of future
research into more exact etiologies for these conditions.
Polyarticular JIA is defined as the JIA type where five
or more joints are involved with either a rheumatoid
factor-positive (on two consecutive tests) or a rheuma-
toid factor-negative further subdivision [1,2]. JIA is said
to be polyarticular if at any time in the first 6 months
from onset the cumulative number of involved joints
reaches five. If this additive total effect only occurs after
6 months from onset then the type is changed from
oligoarticular (up to four joints involved) to extended
oligoarticular (five or more joints after 6 months). In
addition, the JIA subtypes of systemic onset JIA and
enthesitis related JIA, as well as psoriatic JIA, can also
involve five or more joints. If the other associated defin-
ing features of any these particular groups are missing
or overlooked, it is possible for a clinical case to be
assigned to the incorrect group. Indeed, there may be
some false divisions between the various subtypes if
polyarticular arthritis is the main feature. However,
there are still too few studies with large enough sub-
groups of patients with all the subtypes to know if the
ILAR classification criteria for subtypes is truly clinically
relevant from a therapeutic point of view in disease with
polyarticular involvement. There is no single diagnostic
test for any of the subtypes of JIA apart from a persis-
tently raised rheumatoid factor level in the absence of
connective tissues disorders.
The incidence of JIA is approximately 1:10,000, with a
prevalence in the population of around 1:1,000 and
about one-third of cases being polyarticular in nature
[3,4]. This subtype may affect from five to most joints,
can cause erosive disease, joint deformities with damage
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to growth plates, reduced mobility and general debility
from chronic inflammation. It is associated with long-
term disease activity into adult life in over 60% of cases.
Treatment to achieve clinical remission is therefore
vital, but the exact algorithm of care to achieve full
remission has still not been established and there is con-
siderable variation between centers based on clinical
experience.
The role of methotrexate in the polyarticular subtype
is secure after controlled trials in relatively large num-
bers of patients [5-7]. Biologic therapies including anti-
tumor necrosis factor (TNF) blockers have been shown
to improve disease activity, but all treatment studies
seem to plateau with 75% to 85% of patients responding
at significant response levels [8]. Steroids are used in
different ways, with short-term intravenous courses of
methylprednisolone or one-off intramuscular depot
injections and/or multiple and repeated intra-articular
injections being favored by some with others using
more long-term regimes of low dose oral steroids
[9-11]. For difficult unresponsive and damaging disease
there are suggestions that Rituximab use may have an
important role [12]. So far, complete and sustained clini-
cal remission allowing for complete withdrawal of treat-
ment is rarely reported, and yet this remains the long-
term aim of all treatment attempts [13-16].
The TREAT trial: main findings and strengths of
the study design
There have been no studies in JIA designed to investi-
gate an initial aggressive approach to treatment with an
aim of early complete disease remission, although many
clinicians individualize treatments in an effort to achieve
this. The TREAT trial [17] compared subcutaneous
methotrexate at 0.5 mg/kg/week to a maximum of 40
mg plus two placebos with the same methotrexate
regime plus subcutaneous etanercept 0.8 mg/kg/week
(maximum 50 mg) and oral prednisolone 0.5 mg/kg/day
(maximum 60 mg) tapered to 0 mg by 17 weeks.
The ambitious primary outcome was set as clinical
inactive disease [18] at 6 months with clinical remission
on medication within 12 months of treatment also
assessed (defined as a continuous 6 months of clinically
inactive disease while receiving medication).
The strength of this study was that it attempted to use
the ‘window of opportunity’ approach for long-lasting
disease control from aggressive initial treatment [13].
Rather than simply looking for improvement using the
usual American College of Rheumatology (ACR) Paedia-
tric 70 response rates (70% improvement) the much
more stringent primary outcome of clinically inactive
disease was used. Assessment of two active treatments
versus two concurrent placebos was also a strength, as it
involved analyzing a treatment algorithm rather than
looking at a single drug effect.
The main finding of the study was that after 12
months clinical remission on treatment was achieved in
significantly more patients in the intensive treatment
group than in the placebo and methotrexate group (P =
0.0534).
Potentially the most important finding of the study
was that the shorter the disease duration was at base-
line, the more likely it was that clinically inactive disease
would be achieved by 6 months. For each month sooner
after disease onset the aggressive treatment was begun,
the more likely it was that clinical remission at 6
months would be achieved, and this was to a factor of
1.324 per month earlier. This finding does support the
very important suggestion of a ‘window of opportunity’
for easier and more long-lasting disease control [13].
Limitations of the TREAT trial
There were disappointingly small numbers of patients
achieving clinical remission on treatment by 12 months
with 9/42 (21%) in the full treatment arm and 3/43 (7%)
in the methotrexate and double placebo arm, suggesting
that although this difference was statistically significant
the treatment regime itself is unlikely to be the break-
through in terms of the majority of patients that we are
seeking. However, these patients had very severe disease
and a large proportion (33% to 40%) had rheumatoid
factor positivity.
The randomization process did allocate more severe
patients to the placebo arm in terms of more active
joints and a significantly higher erythrocyte sedimenta-
tion rate (ESR) in the placebo arm, but this should really
have served to accentuate the effect of the full treatment
regime. This study demonstrated how effective injected
weekly methotrexate can be given early in the disease
course.
The relatively large numbers of patients discontinuing
complex studies such as this provides a warning to
investigators to include larger numbers of patients than
the strict power calculations allow in order that the final
numbers in each group remain meaningful. Larger num-
bers also allow for more subanalyses to be carried out in
the explanation of results.
It is possible that once-weekly etanercept is not as
effective as twice-weekly etanercept in the initial phases
of treatment and that oral prednisolone is not as effec-
tive as intramuscular, intravenous or multiple intra-
articular routes of steroid administration. The definition
of clinically inactive disease may have been too stringent
in this study with the 2011 consensus for provisional
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criteria for definitions containing a few amendments
that may be more realistic [19].
Conclusions
These findings support the need to continue the search
for a rapid initial remission-inducing regime, and yet the
protocol studied does not appear to be that exact
regime. The findings that the earlier treatment is started
the more likely that clinical remission on treatment will
be achieved at 12 months is a fundamental one in
encouraging clinicians and healthcare providers to con-
tinue to be open to new regimes, rather than enshrining
accepted protocols such as National Institute for Health
and Clinical Excellence (NICE)-agreed protocols in prac-
tice forever.
The need now is for a study of ‘tight control’ until
clinical inactive disease is achieved using a personalized
approach, with addition of therapies with short interval
reviews until the patient is fully under control (as has
been shown in adult rheumatoid arthritis), and then to
describe what these regimes require [19-22]. The results
of the TREAT trial are worrying enough to justify more
substantial treatments such as a trial of rituximab on
first diagnosis of polyarticular JIA rather than after fail-
ure of more widely used treatments.
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